Latitude Pharma's Phospholipid Gel tech gains acceptance

With four new collaborative programs announced, San Diego-based Latitude Pharmaceuticals now has a total of eleven projects underway for its Phospholipid Gel (PG) Depot sustained release drug delivery technology. The parenteral drug delivery platform, for both small and large molecule therapeutics, can deliver up to seven days of low burst, peak-free sustained drug release following a subcutaneous or intramuscular injection. 

Says LPI President, Andrew Chen, PhD, “Our latest projects represent a growing recognition from startups to large pharma of the potential for PG Depot technology. We’re very pleased that our newest collaborators have selected (PG Depot) to overcome the short half-life and frequent injection issues problematic for many emerging medicines, especially proteins and peptides.”

- here’s Latitude's release

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.